Mbody AI Ltd. current report, Q4 FY2017

Business Context and Reporting Period

This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period ending November 22, 2017. The registrant is a foreign private issuer based in Isfiya, Israel, reporting on a completed capital raise transaction.

Key Financial Metrics

The filing details a registered direct offering and concurrent private placement rather than standard operating results.

  • Gross Proceeds: Approximately $2.5 million from the sale of 2,272,640 ordinary shares at $1.10 per share.
  • Warrant Issuance: Unregistered five-year warrants issued to purchase up to 1,704,545 ordinary shares at an exercise price of $1.25 per share.
  • Transaction Costs: A 7% fee paid to placement agent H.C. Wainwright & Co., LLC, plus a $60,000 expense reimbursement.
  • Agent Warrants: Warrants issued to the placement agent to purchase up to 113,632 shares at an exercise price of $1.375 per share.

The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the transaction proceeds.

Material Changes

The primary material change is the increase in share capital and the issuance of warrants resulting from the November 22, 2017 closing. This transaction was incorporated by reference into the company's Post-Effective Amendment No. 1 to Form S-8, Form F-3, and Form F-1 registration statements.

Outlook, Risks, and Management Commentary

Management commentary is limited to the execution of the offering. The filing notes that the warrants issued to investors are immediately exercisable. No specific forward-looking guidance, risk factors, or contingencies regarding future operations are detailed in this specific document, though the transaction itself implies a need for capital deployment.

Investor Verification Checklist

  • Verify the dilution impact of the 2,272,640 new shares and the 1,704,545 investor warrants.
  • Confirm the total cash net of the 7% placement fee and $60,000 expense reimbursement.
  • Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants or redemption rights.
  • Check the press release (Exhibit 99.1) for the stated intended use of the $2.5 million proceeds.